Stocks · News reference
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.82) per share. This is a 583.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $6.533 million in sales
Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $64.
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.